Related references
Note: Only part of the references are listed.Cardiovascular and Cancer Risk with Tofacitinib in Rheumatoid Arthritis
Steven R. Ytterberg et al.
NEW ENGLAND JOURNAL OF MEDICINE (2022)
Innovation in the treatment of atopic dermatitis: Emerging topical and oral Janus kinase inhibitors
Chisa Nakashima et al.
ALLERGOLOGY INTERNATIONAL (2022)
Waiting for JAK inhibitor safety data
Tue Wenzel Kragstrup et al.
RMD OPEN (2022)
Efficacy and safety of baricitinib in combination with topical corticosteroids in patients with moderate-to-severe atopic dermatitis with inadequate response, intolerance or contraindication to ciclosporin: results from a randomized, placebo-controlled, phase III clinical trial (BREEZE-AD4)
Thomas Bieber et al.
BRITISH JOURNAL OF DERMATOLOGY (2022)
Upadacitinib plus topical corticosteroids in atopic dermatitis: Week 52 AD Up study results
Jonathan Silverberg et al.
JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY (2022)
Janus kinase inhibitors in dermatology: Part I. A comprehensive review
Stephanie Chapman et al.
JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY (2022)
Abrocitinib induction, randomized withdrawal, and retreatment in patients with moderate-to-severe atopic dermatitis: Results from the JAK1 Atopic Dermatitis Efficacy and Safety (JADE) REGIMEN phase 3 trial
Andrew Blauvelt et al.
JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY (2022)
Phase 3 efficacy and safety of abrocitinib in adults with moderate-to-severe atopic dermatitis after switching from dupilumab (JADE EXTEND)
Vivian Y. Shi et al.
JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY (2022)
Efficacy and Safety of Upadacitinib in Patients With Moderate to Severe Atopic Dermatitis Analysis of Follow-up Data From the Measure Up 1 and Measure Up 2 Randomized Clinical Trials
Eric L. Simpson et al.
JAMA DERMATOLOGY (2022)
Systemic Immunomodulatory Treatments for Atopic Dermatitis Update of a Living Systematic Review and Network Meta-analysis
Aaron M. Drucker et al.
JAMA DERMATOLOGY (2022)
Efficacy and safety of abrocitinib versus dupilumab in adults with moderate-to-severe atopic dermatitis: a randomised, double-blind, multicentre phase 3 trial
Kristian Reich et al.
LANCET (2022)
Association of Risk of Incident Venous Thromboembolism With Atopic Dermatitis and Treatment With Janus Kinase Inhibitors A Systematic Review and Meta-analysis
Tai-Li Chen et al.
JAMA DERMATOLOGY (2022)
Identification of immune-related genes in atopic dermatitis, contact dermatitis, and psoriasis: A bioinformatics analysis
Lian Zhang et al.
DERMATOLOGICA SINICA (2022)
Recommendations on use of systemic treatments for immune-mediated dermatologic disorders in patients with confirmed COVID-19 infection: A rapid review
Chia-Ling Yu et al.
DERMATOLOGICA SINICA (2022)
Phase 3 efficacy and safety of abrocitinib in adults with moderate-to-severe atopic dermatitis after switching from dupilumab (JADE EXTEND)
Vivian Y. Shi et al.
JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY (2022)
Pooled safety analysis of baricitinib in adult patients with atopic dermatitis from 8 randomized clinical trials
T. Bieber et al.
JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY (2021)
Delgocitinib ointment in pediatric patients with atopic dermatitis: A phase 3, randomized, double-blind, vehicle-controlled study and a subsequent open-label, long-term study
Hidemi Nakagawa et al.
JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY (2021)
Baricitinib in patients with moderate-tosevere atopic dermatitis: Results from a randomized monotherapy phase 3 trial in the United States and Canada (BREEZE-AD5)
Eric L. Simpson et al.
JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY (2021)
Molecular Mechanisms of Atopic Dermatitis Pathogenesis
Jowita Sroka-Tomaszewska et al.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES (2021)
Efficacy and safety of ruxolitinib cream for the treatment of atopic dermatitis: Results from 2 phase 3, randomized, double-blind studies
Kim Papp et al.
JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY (2021)
A phase 2a randomized, placebo-controlled study to evaluate the efficacy and safety of the oral Janus kinase inhibitors ritlecitinib and brepocitinib in alopecia areata: 24-week results
Brett King et al.
JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY (2021)
Abrocitinib versus Placebo or Dupilumab for Atopic Dermatitis
Thomas Bieber et al.
NEW ENGLAND JOURNAL OF MEDICINE (2021)
Long-term Efficacy of Baricitinib in Adults With Moderate to Severe Atopic Dermatitis Who Were Treatment Responders or Partial Responders An Extension Study of 2 Randomized Clinical Trials
Jonathan I. Silverberg et al.
JAMA DERMATOLOGY (2021)
Venous Thromboembolism Risk With JAK Inhibitors: A Meta-Analysis
Mark Yates et al.
ARTHRITIS & RHEUMATOLOGY (2021)
The PI3K/Akt Pathway: Emerging Roles in Skin Homeostasis and a Group of Non-Malignant Skin Disorders
Yan Teng et al.
CELLS (2021)
Risk of Venous Thromboembolism Among Patients with Atopic Dermatitis: A Cohort Study in a US Administrative Claims Database
Kristin J. Meyers et al.
DERMATOLOGY AND THERAPY (2021)
Integrated Safety Analysis of Abrocitinib for the Treatment of Moderate-to-Severe Atopic Dermatitis From the Phase II and Phase III Clinical Trial Program
Eric L. Simpson et al.
AMERICAN JOURNAL OF CLINICAL DERMATOLOGY (2021)
Efficacy and Safety of SHR0302, a Highly Selective Janus Kinase 1 Inhibitor, in Patients with Moderate to Severe Atopic Dermatitis: A Phase II Randomized Clinical Trial
Yan Zhao et al.
AMERICAN JOURNAL OF CLINICAL DERMATOLOGY (2021)
Selective Tyrosine Kinase 2 Inhibition for Treatment of Inflammatory Bowel Disease: New Hope on the Rise
Silvio Danese et al.
INFLAMMATORY BOWEL DISEASES (2021)
Efficacy and safety of topical Janus kinase and phosphodiesterase inhibitor-4 inhibitors for the treatment of atopic dermatitis: A network meta-analysis
Lu Zhang et al.
JOURNAL OF DERMATOLOGY (2021)
Safety and efficacy of upadacitinib in combination with topical corticosteroids in adolescents and adults with moderate-to-severe atopic dermatitis (AD Up): results from a randomised, double-blind, placebo-controlled, phase 3 trial
Kristian Reich et al.
LANCET (2021)
Once-daily upadacitinib versus placebo in adolescents and adults with moderate-to-severe atopic dermatitis (Measure Up 1 and Measure Up 2): results from two replicate double- blind, randomised controlled phase 3 trials
Emma Guttman-Yassky et al.
LANCET (2021)
Efficacy and Safety of Abrocitinib in Combination With Topical Therapy in Adolescents With Moderate-to-Severe Atopic Dermatitis The JADE TEEN Randomized Clinical Trial
Lawrence F. Eichenfield et al.
JAMA DERMATOLOGY (2021)
Efficacy and Safety of Upadacitinib vs Dupilumab in Adults With Moderate-to-Severe Atopic Dermatitis A Randomized Clinical Trial
Andrew Blauvelt et al.
JAMA DERMATOLOGY (2021)
Systematic Review on the Efficacy and Safety of Oral Janus Kinase Inhibitors for the Treatment of Atopic Dermatitis
Michelle Le et al.
FRONTIERS IN MEDICINE (2021)
Taiwan dermatological association recommendations for coronavirus disease of 2019 vaccination in patients treated with immunotherapeutics
Chih-Hung Lee et al.
DERMATOLOGICA SINICA (2021)
The JAK/STAT signaling pathway: from bench to clinic
Xiaoyi Hu et al.
SIGNAL TRANSDUCTION AND TARGETED THERAPY (2021)
Interleukin-13: Targeting an underestimated cytokine in atopic dermatitis
Thomas Bieber
ALLERGY (2020)
Treatment of atopic dermatitis with ruxolitinib cream (JAKI/JAK2 inhibitor) or triamcinolone cream
Brian S. Kim et al.
JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY (2020)
Upadacitinib in adults with moderate to severe atopic dermatitis: 16-week results from a randomized, placebo-controlled trial
Emma Guttman-Yassky et al.
JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY (2020)
Baricitinib in patients with moderate-to-severe atopic dermatitis and inadequate response to topical corticosteroids: results from two randomized monotherapy phaseIIItrials
E. L. Simpson et al.
BRITISH JOURNAL OF DERMATOLOGY (2020)
The Role of Th17-Related Cytokines in Atopic Dermatitis
Makoto Sugaya
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES (2020)
Janus kinase inhibitor delgocitinib suppresses pruritus and nerve elongation in an atopic dermatitis murine model
Yasuo Yamamoto et al.
JOURNAL OF DERMATOLOGICAL SCIENCE (2020)
Long-term safety and efficacy of delgocitinib ointment, a topical Janus kinase inhibitor, in adult patients with atopic dermatitis
Hidemi Nakagawa et al.
JOURNAL OF DERMATOLOGY (2020)
Delgocitinib ointment, a topical Janus kinase inhibitor, in adult patients with moderate to severe atopic dermatitis: A phase 3, randomized, double-blind, vehicle-controlled study and an open-label, long-term extension study
Hidemi Nakagawa et al.
JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY (2020)
TYK2/JAK1 Inhibitor PF-06700841 in Patients with Plaque Psoriasis: Phase IIa, Randomized, Double-Blind, Placebo-Controlled Trial
Seth B. Forman et al.
JOURNAL OF INVESTIGATIVE DERMATOLOGY (2020)
Efficacy and Safety of Abrocitinib in Patients With Moderate-to-Severe Atopic Dermatitis A Randomized Clinical Trial
Jonathan Silverberg et al.
JAMA DERMATOLOGY (2020)
Efficacy and safety of abrocitinib in adults and adolescents with moderate-to-severe atopic dermatitis (JADE MONO-1): a multicentre, double-blind, randomised, placebo-controlled, phase 3 trial
Eric L Simpson et al.
LANCET (2020)
Efficacy and Safety of Baricitinib Combined With Topical Corticosteroids for Treatment of Moderate to Severe Atopic Dermatitis A Randomized Clinical Trial
Kristian Reich et al.
JAMA DERMATOLOGY (2020)
16089 Safety of ATI-502, a novel topical JAK1/3 inhibitor, in adults with moderate to severe atopic dermatitis: Results from a phase 2a open-label trial
Stacy Smith et al.
JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY (2020)
The IL-23/IL-17 Pathway in Inflammatory Skin Diseases: From Bench to Bedside
Taoming Liu et al.
FRONTIERS IN IMMUNOLOGY (2020)
Regulation of Skin Barrier Function via Competition between AHR Axis versus IL-13/IL-4-JAK-STAT6/STAT3 Axis: Pathogenic and Therapeutic Implications in Atopic Dermatitis
Masutaka Furue
JOURNAL OF CLINICAL MEDICINE (2020)
Association of atopic dermatitis with inflammatory bowel disease: A systematic review and meta-analysis
Chi-Hui Wang et al.
DERMATOLOGICA SINICA (2020)
Atopic dermatitis: Tofacitinib, an option for refractory disease
Sineida Berbert Ferreira et al.
CLINICAL CASE REPORTS (2020)
A study on the knowledge, attitudes, and practices of Asian dermatologists in the management of atopic dermatitis
Siqing Ee et al.
DERMATOLOGICA SINICA (2020)
Baricitinib in adult patients with moderate-to-severe atopic dermatitis: A phase 2 parallel, double-blinded, randomized placebo-controlled multiple-dose study
Emma Guttman-Yassky et al.
JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY (2019)
Baseline IL-22 expression in patients with atopic dermatitis stratifies tissue responses to fezakinumab
Patrick M. Brunner et al.
JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY (2019)
A systematic review and meta-analysis of infection risk with small molecule JAK inhibitors in rheumatoid arthritis
Katie Bechman et al.
RHEUMATOLOGY (2019)
Oral Janus kinase/SYK inhibition (ASN002) suppresses inflammation and improves epidermal barrier markers in patients with atopic dermatitis
Ana B. Pavel et al.
JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY (2019)
The IL-12 Cytokine and Receptor Family in Graft-vs.-Host Disease
David Bastian et al.
FRONTIERS IN IMMUNOLOGY (2019)
Phase 2 clinical study of delgocitinib ointment in pediatric patients with atopic dermatitis
Hidemi Nakagawa et al.
JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY (2019)
JAK Inhibitors for Atopic Dermatitis: An Update
Helen He et al.
AMERICAN JOURNAL OF CLINICAL DERMATOLOGY (2019)
Efficacy and Safety of Oral Janus Kinase 1 Inhibitor Abrocitinib for Patients With Atopic Dermatitis A Phase 2 Randomized Clinical Trial
Melinda J. Gooderham et al.
JAMA DERMATOLOGY (2019)
JAK/STAT Cytokine Signaling at the Crossroad of NK Cell Development and Maturation
Dagmar Gotthardt et al.
FRONTIERS IN IMMUNOLOGY (2019)
Chronic inflammation in the etiology of disease across the life span
David Furman et al.
NATURE MEDICINE (2019)
The impact of lifestyle factors on evolution of atopic dermatitis: An alternative approach
Iulia Solomon et al.
EXPERIMENTAL AND THERAPEUTIC MEDICINE (2019)
Interleukin-5 in the Pathophysiology of Severe Asthma
Corrado Pelaia et al.
FRONTIERS IN PHYSIOLOGY (2019)
Risk of venous thromboembolism in patients with psoriatic arthritis, psoriasis and rheumatoid arthritis: a general population-based cohort study
Alexis Ogdie et al.
EUROPEAN HEART JOURNAL (2018)
JAK/STAT inhibitors and other small molecule cytokine antagonists for the treatment of allergic disease
Michael D. Howell et al.
ANNALS OF ALLERGY ASTHMA & IMMUNOLOGY (2018)
Efficacy and safety of topical JTE-052, a Janus kinase inhibitor, in Japanese adult patients with moderate-to-severe atopic dermatitis: a phase II, multicentre, randomized, vehicle-controlled clinical study
H. Nakagawa et al.
BRITISH JOURNAL OF DERMATOLOGY (2018)
Dupilumab: A review of its use in the treatment of atopic dermatitis
Melinda J. Gooderham et al.
JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY (2018)
IL-33/IL-31 Axis: A Potential Inflammatory Pathway
Eleonora Di Salvo et al.
MEDIATORS OF INFLAMMATION (2018)
Central inhibition of granulocyte-macrophage colony-stimulating factor is analgesic in experimental neuropathic pain
Louise S. C. Nicol et al.
PAIN (2018)
The molecular details of cytokine signaling via the JAK/STAT pathway
Rhiannon Morris et al.
PROTEIN SCIENCE (2018)
New Cytokines in the Pathogenesis of Atopic Dermatitis-New Therapeutic Targets
Jolanta Klonowska et al.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES (2018)
Atopic dermatitis is associated with anxiety, depression, and suicidal ideation, but not with psychiatric hospitalization or suicide
J. P. Thyssen et al.
ALLERGY (2018)
Itch in Atopic Dermatitis
Makiko Kido-Nakahara et al.
IMMUNOLOGY AND ALLERGY CLINICS OF NORTH AMERICA (2017)
The immunology of atopic dermatitis and its reversibility with broad-spectrum and targeted therapies
Patrick M. Brunner et al.
JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY (2017)
JAK inhibitors in dermatology: The promise of a new drug class
William Damsky et al.
JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY (2017)
Inhibition of JAK/STAT pathway restrains TSLP-activated dendritic cells mediated inflammatory T helper type 2 cell response in allergic rhinitis
Zhaohui Shi et al.
MOLECULAR AND CELLULAR BIOCHEMISTRY (2017)
JAK inhibition as a therapeutic strategy for immune and inflammatory diseases
Daniella M. Schwartz et al.
NATURE REVIEWS DRUG DISCOVERY (2017)
Severe eosinophilic asthma: from the pathogenic role of interleukin-5 to the therapeutic action of mepolizumab
Corrado Pelaia et al.
DRUG DESIGN DEVELOPMENT AND THERAPY (2017)
Genome-wide Analysis of STAT3-Mediated Transcription during Early Human Th17 Cell Differentiation
Subhash K. Tripathi et al.
CELL REPORTS (2017)
The etiopathogenesis of atopic dermatitis: barrier disruption, immunological derangement, and pruritus
Pawinee Rerknimitr et al.
INFLAMMATION AND REGENERATION (2017)
Mediators of Chronic Pruritus in Atopic Dermatitis: Getting the Itch Out?
Nicholas K. Mollanazar et al.
CLINICAL REVIEWS IN ALLERGY & IMMUNOLOGY (2016)
Targeting key proximal drivers of type 2 inflammation in disease
Namita A. Gandhi et al.
NATURE REVIEWS DRUG DISCOVERY (2016)
Topical tofacitinib for atopic dermatitis: a phase IIa randomized trial
R. Bissonnette et al.
BRITISH JOURNAL OF DERMATOLOGY (2016)
The pruritus- and TH2-associated cytokine IL-31 promotes growth of sensory nerves
Micha Feld et al.
JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY (2016)
Hyperactivation of JAK1 tyrosine kinase induces stepwise, progressive pruritic dermatitis
Takuwa Yasuda et al.
JOURNAL OF CLINICAL INVESTIGATION (2016)
Two Phase 3 Trials of Dupilumab versus Placebo in Atopic Dermatitis
E. L. Simpson et al.
NEW ENGLAND JOURNAL OF MEDICINE (2016)
Interleukin-22: Immunobiology and Pathology
Jarrod A. Dudakov et al.
ANNUAL REVIEW OF IMMUNOLOGY VOL 33 (2015)
Pathogenesis of atopic dermatitis
W. Peng et al.
CLINICAL AND EXPERIMENTAL ALLERGY (2015)
The Janus kinase inhibitor JTE-052 improves skin barrier function through suppressing signal transducer and activator of transcription 3 signaling
Wataru Amano et al.
JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY (2015)
Treatment of recalcitrant atopic dermatitis with the oral Janus kinase inhibitor tofacitinib citrate
Lauren L. Levy et al.
JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY (2015)
STAT3-dependent reactive astrogliosis in the spinal dorsal horn underlies chronic itch
Miho Shiratori-Hayashi et al.
NATURE MEDICINE (2015)
Th17 cells and tissue remodeling in atopic and contact dermatitis
D. Simon et al.
ALLERGY (2014)
The molecular regulation of Janus kinase (JAK) activation
Jeffrey J. Babon et al.
BIOCHEMICAL JOURNAL (2014)
Deciphering the complexities of atopic dermatitis: Shifting paradigms in treatment approaches
Donald Y. M. Leung et al.
JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY (2014)
Dupilumab improves the molecular signature in skin of patients with moderate-to-severe atopic dermatitis
Jennifer D. Hamilton et al.
JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY (2014)
A sensory neuron-expressed IL-31 receptor mediates T helper cell-dependent itch: Involvement of TRPV1 and TRPA1
Ferda Cevikbas et al.
JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY (2014)
Interferon-γ Decreases Ceramides with Long-Chain Fatty Acids: Possible Involvement in Atopic Dermatitis and Psoriasis
Chisato Tawada et al.
JOURNAL OF INVESTIGATIVE DERMATOLOGY (2014)
Meta-analysis: the risk of venous thromboembolism in patients with inflammatory bowel disease
H. Yuhara et al.
ALIMENTARY PHARMACOLOGY & THERAPEUTICS (2013)
Investigating International Time Trends in the Incidence and Prevalence of Atopic Eczema 1990-2010: A Systematic Review of Epidemiological Studies
Ivette A. G. Deckers et al.
PLOS ONE (2012)
Interleukin-17 Contributes to Neuroinflammation and Neuropathic Pain Following Peripheral Nerve Injury in Mice
Cristina Fabiola Kim et al.
JOURNAL OF PAIN (2011)
Role of TNF-alpha during central sensitization in preclinical studies
Pablo Andrade et al.
NEUROLOGICAL SCIENCES (2011)
Diverse Targets of the Transcription Factor STAT3 Contribute to T Cell Pathogenicity and Homeostasis
Lydia Durant et al.
IMMUNITY (2010)
Thymic stromal lymphopoietin-mediated STAT5 phosphorylation via kinases JAK1 and JAK2 reveals a key difference from IL-7-induced signaling
Yrina Rochman et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2010)
Atopic Dermatitis: A Disease Caused by Innate Immune Defects?
Anna De Benedetto et al.
JOURNAL OF INVESTIGATIVE DERMATOLOGY (2009)
Structure and signalling in the IL-17 receptor family
Sarah L. Gaffen
NATURE REVIEWS IMMUNOLOGY (2009)
Structures and biological functions of IL-31 and IL-31 receptors
Qing Zhang et al.
CYTOKINE & GROWTH FACTOR REVIEWS (2008)
Possible Pathogenic Role of Th17 Cells for Atopic Dermatitis
Chizuko Koga et al.
JOURNAL OF INVESTIGATIVE DERMATOLOGY (2008)
Mechanisms of disease: Atopic dermatitis
Thomas Bieber
NEW ENGLAND JOURNAL OF MEDICINE (2008)
Inteferons pen the JAK-STAT pathway
Christian Schindler et al.
SEMINARS IN CELL & DEVELOPMENTAL BIOLOGY (2008)
IL-31: A new link between T cells and pruritus in atopic skin inflammation
E Sonkoly et al.
JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY (2006)
Interleukin-22 (IL-22) activates the JAK/STAT, ERK, JNK, and p38 MAP kinase pathways in a rat hepatoma cell line - Pathways that are shared with and distinct from IL-10
D Lejeune et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2002)
Cloning of a receptor subunit required for signaling by thymic stromal lymphopoietin
A Pandey et al.
NATURE IMMUNOLOGY (2000)
IL-4/IL-13 signaling beyond JAK/STAT
H Jiang et al.
JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY (2000)